CYP2C19 metabolizer phenotype and recurrent documented gastroesophageal reflux disease after proton pump inhibitor initiation: A cohort study from the All of Us Research Program
Annals of Pharmacotherapy · 21.11.2026
DOI: 10.1177/10600280261505458 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 21.11.2026. Verfasst von Maxwell Trettin und 1 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
CYP2C19 influences proton pump inhibitor (PPI) exposure, but its association with longitudinal gastroesophageal reflux disease (GERD) documentation remains uncertain.
Objective
To evaluate associations between CYP2C19 phenotype and documented GERD outcomes after PPI initiation.
Methods
This retrospective All of Us cohort included 21,135 adults with GERD, a definitive CYP2C19 phenotype, and 365-day post-index observation. Recurrent documented GERD required at least 2 diagnosis dates occurring from day 31 to day 365 separated by at least 30 days. Modified Poisson regression estimated adjusted risk ratios (ARRs). A secondary composite assessed reflux testing or antireflux interventions.
Results
Recurrent documented GERD occurred in 5,927 participants (28.0%). Compared with normal metabolizers, ARRs (95% CI) were 1.11 (0.97-1.26) for poor, 1.02 (0.97-1.07) for intermediate, 1.04 (0.98-1.09) for rapid, and 0.97 (0.87-1.08) for ultrarapid metabolizers (global P = .353). Estimates were similar across alternative documentation definitions, ancestral alignment, and the restriction to omeprazole only. Among 20 928 secondary analysis participants, 245 (1.17%) underwent further reflux testing or intervention (global P = .679). Dose and ongoing exposure were not modeled. Conclusion and Relevance: CYP2C19 phenotype was not significantly associated with these documentation-based outcomes. This large genomic cohort extends evidence to longitudinal health care records, but exposure uncertainty and multifactorial GERD limit inferences about active treatment responses. The findings do not establish equivalence or justify changing genotype-guided dosing recommendations; clinical decisions should also consider dose, adherence, and the underlying symptom mechanisms.
Zitieren
APA
Trettin, M., & Holt, M. (2026). CYP2C19 metabolizer phenotype and recurrent documented gastroesophageal reflux disease after proton pump inhibitor initiation: A cohort study from the All of Us Research Program. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261505458
Vancouver
Trettin M, Holt M. CYP2C19 metabolizer phenotype and recurrent documented gastroesophageal reflux disease after proton pump inhibitor initiation: A cohort study from the All of Us Research Program. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261505458
BibTeX
@article{Trettin2026,
author = {Trettin, Maxwell and Holt, Matthew},
title = {CYP2C19 metabolizer phenotype and recurrent documented gastroesophageal reflux disease after proton pump inhibitor initiation: A cohort study from the All of Us Research Program},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261505458}
}
EUVIMED